Valuation: RenovoRx, Inc.

Market Cap 43.22M 37.57M 34.97M 32.11M 60.63M 4.13B 61.57M 412M 162M 2.05B 162M 159M 6.89B P/E 2026 *
-3.23x
P/E 2027 * -6.5x
Enterprise Value 43.22M 37.57M 34.97M 32.11M 60.63M 4.13B 61.57M 412M 162M 2.05B 162M 159M 6.89B EV / Sales 2026 *
13.5x
EV / Sales 2027 * 3.52x
Free-Float
96.58%
Yield 2026 *
-
Yield 2027 * -
06-23 RenovoRx, Inc. Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, Jun-23-2026 12:30 PM
06-11 RenovoRx Announces Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP In Locally Advanced Pancreatic Cancer CI
06-01 RenovoRx, Inc., Q1 2026 Earnings Call, May 14, 2026
05-28 RenovoRx gets FDA orphan drug designation for oxaliplatin to treat pancreatic cancer RE
05-26 Renovorx Publishes Pharmacokinetic and Pharmacodynamic Sub-Study Results from Ongoing Phase III TIGeR-PaC Clinical Trial Evaluating Tamp Platform for Targeted Intra-Arterial Delivery of Gemcitabine CI
05-14 RenovoRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-14 RenovoRx, Inc. Announces Advancement of the Ongoing Phase III TIGeR-PaC Clinical Trial Evaluating Intra-Arterial Delivery of Gemcitabine CI
05-14 RenovoRx, Inc. Reiterates Earnings Guidance for 2026 CI
04-14 RenovoRx Inc Presents Clinical Data Supporting Targeted Chemotherapeutic Delivery Via Tamp Therapy Platform CI
04-08 RenovoRx Secures First Notice Of Allowance For Japanese Patent Covering RenovoCath Device For Targeted Local Drug-Delivery Via The Vasa Vasorum CI
03-30 RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-27 RenovoRx, Inc. Appoints Ramtin Agah, M.D. As Executive Chairman , Effective February 27, 2026 CI
03-26 RenovoRx, Inc. Announces Key Phase III Milestone as TIGeR-PaC Trial Surpasses 100 Randomized Patients CI
1 day+1.82%
1 week+10.75%
1 month+0.32%
3 months+8.49%
6 months-7.86%
Current year+14.07%
1 week 0.87
Extreme 0.871
0.98
1 month 0.83
Extreme 0.83
0.98
Current year 0.77
Extreme 0.77
1.3
1 year 0.7
Extreme 0.7006
1.45
3 years 0.53
Extreme 0.5306
2.35
5 years 0.53
Extreme 0.5306
16.74
10 years 0.53
Extreme 0.5306
16.74
Manager TitleAgeSince
Chief Executive Officer 49 2014-10-26
Chief Tech/Sci/R&D Officer 60 2009-11-30
Director of Finance/CFO 71 2026-02-02
Director TitleAgeSince
Director/Board Member 82 2012-11-30
Chairman 60 2018-04-30
Director/Board Member 84 2011-12-31
Date Insider Type Main position Quantity % Market Cap.
4/3/26 Free

Chief Executive Officer

946,107 2.5815%
2/4/26 Other

Chief Financial Officer

25,000 0.0682%
1/21/26 Buy

Founder

10,000 0.0273%
Change 5-day change 1-year change 3-year change Capi.($)
+1.82%+10.75%-20.80%-52.32% 43.22M
-1.01%+13.03%-36.69%-57.83% 102M
-.--%-0.27%-5.18%-60.16% 93.94M
+2.15%+16.76%+107.51%+13.36% 83.02M
Average +0.74%+10.07%+11.21%-39.24% 80.56M
Weighted average by Cap. +0.48%+9.81%+11.77%-39.43%

Financials

2026 *2027 *
Net sales 3.21M 2.79M 2.59M 2.38M 4.5M 306M 4.57M 30.58M 12M 152M 12.04M 11.78M 511M 12.29M 10.69M 9.95M 9.13M 17.24M 1.17B 17.51M 117M 46.01M 584M 46.16M 45.15M 1.96B
Net income -13.04M -11.33M -10.55M -9.69M -18.29M -1.24B -18.57M -124M -48.8M -620M -48.97M -47.89M -2.08B -7.33M -6.37M -5.93M -5.44M -10.28M -699M -10.44M -69.88M -27.43M -348M -27.52M -26.91M -1.17B
Net Debt - -
Logo RenovoRx, Inc.
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Employees
-
Date Price Change Volume
26-07-31 US$0.9583 +1.82% 244,991
26-07-30 US$0.9412 +4.80% 113,573
26-07-29 US$0.8981 -1.01% 127,619
26-07-28 US$0.9073 -5.99% 219,740
26-07-27 US$0.9651 +11.53% 868,804
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9583USD
Average target price
7.030USD
Spread / Average Target
+633.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RNXT Stock